Drug duo aims to turn inoperable lung cancer into surgical candidates

NCT ID NCT07323056

Recruiting now Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two drugs, sacituzumab tirumotecan and limertinib, can shrink EGFR-mutant lung cancer enough to allow surgery. About 36 adults with advanced but potentially removable lung cancer will receive the combination before surgery. The goal is to see how many patients have no cancer left after treatment and to find markers that predict who benefits most.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR-MUTANT NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR-MUTANT NON-SMALL CELL LUNG CANCER POTENTIALLY RESECTABLE

Contacts and locations

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.